혈뇨 치료 시장 규모, 점유율 및 동향 분석 보고서 : 치료 유형별, 유형별, 지역별, 부문 예측(2025-2033년)

Hematuria Treatment Market Summary

The global hematuria treatment market size was estimated at USD 1,087.3 million in 2024 and is projected to reach USD 1,426.9 million by 2033, growing at a CAGR of 3.1% from 2025 to 2033. The market is driven by urological care and sustained by the growing prevalence of recurrent urinary tract infections, bladder cancer, and urolithiasis, alongside an expanding geriatric population.

Hematuria is the most common and vital early clinical sign for bladder cancer, which is a high-burden disease that requires extensive diagnostic and therapeutic resources. Moreover, the increasing incidence of bladder cancer cases globally is expected to drive the overall market growth. In the U.S., the American Cancer Society projects 84,870 new cases in 2025, reflecting stable incidence and continued reliance on diagnostic cystoscopy. Given that most bladder cancers require ongoing surveillance through repeated cystoscopy and risk-adapted intravesical therapy, rising case volumes drive the hematuria treatment industry.

Furthermore, rising urinary tract infection (UTI) incidence increases episodic hematuria presentations and empirical antibiotic use, which drives urgent evaluation demand and creates pressure for faster, point-of-care diagnostics. New rapid diagnostics have shortened pathogen identification, directly affecting hematuria treatment pathways by shortening time-to-diagnosis.

Urolithiasis prevalence and symptomatic stone events are important non-neoplastic causes of visible hematuria and often require definitive endourologic care (URS, PCNL) or imaging triage. Although some age-standardised rates have declined, absolute case counts, and new presentations have risen in many regions. It is characterized by symptoms and a high likelihood of recurrence and has created a considerable burden on the healthcare system, especially affecting individuals aged 20 to 54. This indicates substantial age-standardized incidence of stone disease and rising rates in many regions, which raises emergency and elective procedure volumes. Diagnostic cystoscopy remains among the most frequently performed urology procedures, so rising stone and hematuria referrals drive the industry.

Global Hematuria Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hematuria treatment market report based on treatment type, type, and region:

• Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmacotherapy
• Procedural / Interventional Therapies
• Adjunctive / Supportive Therapies
• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Branded
• Generic
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment type
  • 1.2.2. Type
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment type outlook
  • 2.2.2. Type outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Hematuria Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Hematuria Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Hematuria Treatment Market: Treatment Type Estimates & Trend Analysis

• 4.1. Treatment Type Segment Dashboard
• 4.2. Hematuria Treatment Market: Treatment Type Movement Analysis
• 4.3. Global Hematuria Treatment Market Size & Trend Analysis, by Treatment Type, 2021 to 2033 (USD Million)
  • 4.3.1. Pharmacotherapy
    • 4.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.3.2. Procedural / Interventional Therapies
    • 4.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.3.3. Adjunctive / Supportive Therapies
    • 4.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Hematuria Treatment Market: Type Estimates & Trend Analysis

• 5.1. Type Segment Dashboard
• 5.2. Hematuria Treatment Market: Type Movement Analysis
• 5.3. Global Hematuria Treatment Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 5.3.1. Branded
    • 5.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.2. Generic
    • 5.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Hematuria Treatment Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Dashboard
• 6.2. Regional Market Share Analysis, 2024 & 2030
• 6.3. Hematuria Treatment Market by Region: Key Takeaways
• 6.4. North America
  • 6.4.1. U.S.
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.2. Canada
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Europe
  • 6.5.1. Germany
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.3. France
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.4. Italy
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.5. Spain
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.6. Denmark
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.7. Sweden
    • 6.5.7.1. Key country dynamics
    • 6.5.7.2. Regulatory framework/reimbursement structure
    • 6.5.7.3. Competitive scenario
    • 6.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.8. Norway
    • 6.5.8.1. Key country dynamics
    • 6.5.8.2. Regulatory framework/reimbursement structure
    • 6.5.8.3. Competitive scenario
    • 6.5.8.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Japan
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6.2. China
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6.3. India
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6.4. South Korea
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/reimbursement structure
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/reimbursement structure
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6.6. Thailand
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/reimbursement structure
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. Latin America
  • 6.7.1. Brazil
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7.2. Mexico
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 6.8. MEA
  • 6.8.1. South Africa
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/reimbursement structure
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.8.2. Saudi Arabia
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/reimbursement structure
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.8.3. UAE
    • 6.8.3.1. Key country dynamics
    • 6.8.3.2. Regulatory framework/reimbursement structure
    • 6.8.3.3. Competitive scenario
    • 6.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.8.4. Kuwait
    • 6.8.4.1. Key country dynamics
    • 6.8.4.2. Regulatory framework/reimbursement structure
    • 6.8.4.3. Competitive scenario
    • 6.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. Key company heat map analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. AstraZeneca
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Bristol-Myers Squibb Company
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. F. Hoffmann-La Roche Ltd.
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Johnson & Johnson and its affiliates
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. Merck & Co., Inc.
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Novartis AG
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Pfizer Inc.
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. Sun Pharmaceutical Industries Ltd.
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiativesa